Abbvie Inc
NYSE: ABBV
$176.95
+$5.22 (+3.0%)
Closing Price on November 22, 2024
ABBV Articles
AbbVie shares took a big step back last week after the firm reported less than favorable results for its relapsed/refractory small cell lung cancer trial.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, American Water, Carnival, Cisco, Darden, DexCom, Micron Technology, Nike and Occidental Petroleum.
Published:
Last Updated:
Thursday was an absolute disaster for the broad U.S. markets. There didn’t seem to be anything positive about Thursday for any of the major indices. The Dow was the biggest loser of the group, it...
Published:
Last Updated:
AbbVie saw its shares pull back on Thursday after it reported less than favorable midstage results for its relapsed/refractory small cell lung cancer trial.
Published:
Last Updated:
Jefferies has made a big move by adding a top retail company to its well-respected Franchise Picks list of stocks to Buy.
Published:
Last Updated:
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
Published:
Last Updated:
These five stocks come with upward earnings revisions and the potential for rising dividends. They all make good sense for investors looking for stocks ideas as we get closer to the second quarter.
Published:
Last Updated:
These were 13 stock buyback and dividend hike announcements from the week of February 16 that were simply too large to be ignored.
Published:
Last Updated:
AbbVie is joining the companies raising their shareholder rewards. The pharmaceutical products maker has announced how it will further commit to previously forecast moves.
Published:
Last Updated:
The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
While not the most exciting companies in the world, these five Dividend Aristocrats will certainly hold up much better than others should the market take a deep dive.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include AbbVie, Apple, Exact Sciences, Freeport-McMoran, Laboratory Corp and Splunk.
Published:
Last Updated:
Friday was a positive day for the U.S. markets. We are currently in the midst of the fourth quarter earnings season and so far it has been very positive for the markets, pushing all of the exchanges...
Published:
Last Updated:
AbbVie reported better-than-expected fourth-quarter financial results before the markets opened on Friday.
Published: